Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase

Liu, Fei; Wei, Jiazhang; Hao, Yanrong; Lan, Jiao; Li, Wei; Weng, Jingjin; Li, Min; Su, Cheng Yao; Li, Bing; Mo, Mingzheng; Tang, Fengzhu; Wang, Yongli; Yong, Yang; Jiao, Wei; Qu, Shenhong

doi:10.1080/21655979.2021.1979317

Cited by 17 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The differentially expressed mRNAs are mainly involved in carbohydrate and lipid metabolism. We have found that key genes of lipid pathways, such as sterol regulatory elementbinding transcription factor 1 (SREBF1) and fatty acid synthase (Liu et al, 2019;Liu et al, 2021a), are involved, but a role for glucose transporter 1 (GLUT1) in NPC was not validated in our study (Liu et al, 2019).…”

Section: Introductioncontrasting

confidence: 56%

ZBTB7A governs 2-DG-inhibited glycolysis by regulating GLUT1 in nasopharyngeal carcinoma

LIU¹,

Wei²,

Lan³

et al. 2022

Biocell

Self Cite

View full text Add to dashboard Cite

Our previous studies suggested a potential interaction between the POK erythroid myeloid ontogenic factor ZBTB7A and glucose transporter 1 (GLUT1) in nasopharyngeal carcinoma (NPC). This study was designed to confirm the interaction and further evaluate the precise mechanism by which ZBTB7A and GLUT1 regulate NPC development. The binding sites between ZBTB7A and the promoter of GLUT1 were predicted by bioinformatics.Gene expression was measured by quantitative real-time polymerase chain reaction (qPCR), western blotting, and immunohistochemistry. The activities of key glycolysis enzymes, including hexokinase (HK), pyruvate kinase (PK), lactate dehydrogenase (LDH), and lactate, were detected using specific enzyme-linked immunosorbent assay kits. The connection between ZBTB7A and GLUT1 was analyzed by dual-luciferase reporter assay and chromatin immunoprecipitation-qPCR. The vitality, proliferation, and tumorigenicity of the cells expressing different levels of ZBTB7A were tested by adding the glycolysis inhibitor 2-deoxy-D-glucose (2-DG), followed by MTT, colorimetric focus forming, and xenograft assays, respectively. Our results showed that high expression of GLUT1 was associated with late-stage NPC. After constructing stably transfected cells with lentiviruses, ZBTB7A was effectively knocked down in 5-8F cells (RNAi-5-8F) and overexpressed in 6-10B cells (ZBTB7A-6-10B). The up-or downregulation of GLUT1 secondary to ZBTB7A changes was also limited. The vitality and proliferation of the cells expressing low ZBTB7A were notably blocked by 2-DG. The cells expressing high ZBTB7A were not very sensitive to 2-DG. The growth of RNAi-5-8F xenografts was strongly suppressed by 2-DG. The activities of HK, PK, and LDH were suppressed by 2-DG in the cells expressing low ZBTB7A. RNAi-5-8F cells had the lowest 2-DG-induced lactate production. ZBTB7A directly suppressed the promoter region of GLUT1 to regulate GLUT1 expression. Thus, ZBTB7A controls the 2-DG-induced inhibition of glycolysis by affecting GLUT1.

show abstract

Section: Introductioncontrasting

confidence: 56%

ZBTB7A governs 2-DG-inhibited glycolysis by regulating GLUT1 in nasopharyngeal carcinoma

LIU¹,

Wei²,

Lan³

et al. 2022

Biocell

Self Cite

View full text Add to dashboard Cite

show abstract

“…Collectively, SREBP-1-regulated lipid metabolism is essential for the cancer progression of the urinogenital system, including endometrial, ovarian, and bladder cancer and renal cell carcinomas. The results from cell lines and clinical tissues demonstrate that long intergenic non-protein-coding RNA 02570 can adsorb miRNA-4649-3p to upregulate SREBP-1 and FASN, which promotes the progression of nasopharyngeal carcinoma (NPC) ( 130 ). Epstein–Barr virus-encoded latent membrane protein 1 is expressed in NPC and increases the maturation and activation of SREBP-1 to induce de novo lipid synthesis in the tumor growth and metastasis, which can be inhibited by two inhibitors, luteolin and fatostatin ( 131 ).…”

Section: Other Cancersmentioning

confidence: 99%

Targeting SREBP-1-Mediated Lipogenesis as Potential Strategies for Cancer

2022

View full text Add to dashboard Cite

Sterol regulatory element binding protein-1 (SREBP-1), a transcription factor with a basic helix–loop–helix leucine zipper, has two isoforms, SREBP-1a and SREBP-1c, derived from the same gene for regulating the genes of lipogenesis, including acetyl-CoA carboxylase, fatty acid synthase, and stearoyl-CoA desaturase. Importantly, SREBP-1 participates in metabolic reprogramming of various cancers and has been a biomarker for the prognosis or drug efficacy for the patients with cancer. In this review, we first introduced the structure, activation, and key upstream signaling pathway of SREBP-1. Then, the potential targets and molecular mechanisms of SREBP-1-regulated lipogenesis in various types of cancer, such as colorectal, prostate, breast, and hepatocellular cancer, were summarized. We also discussed potential therapies targeting the SREBP-1-regulated pathway by small molecules, natural products, or the extracts of herbs against tumor progression. This review could provide new insights in understanding advanced findings about SREBP-1-mediated lipogenesis in cancer and its potential as a target for cancer therapeutics.

show abstract

“…Importantly, the TF most significantly involved in FASN regulation, SREBF1, also plays an important role in lipid metabolism ( 45 , 46 ). Recent studies also reported that multiple lncRNAs competitively bind miRNAs to regulate FASN expression in nasopharyngeal and endometrial cancer ( 47 , 48 ). For drugs targeting FASN, a phase II clinical trial revealed that temsirolimus show potential benefit in bladder cancer patients who are refractory to first line platinum-based chemotherapy ( 49 ).…”

Section: Discussionmentioning

confidence: 99%

Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer

et al. 2022

View full text Add to dashboard Cite

Fatty acid metabolism (FAM) genes are potentially useful for predicting prognosis and immunotherapy response in bladder cancer (BC). To examine this, we constructed a prognostic model and identified key FAM genes in BC. Using transcriptional expression profiles and clinical data of BC patients from public datasets and Changhai (CH) hospital, we built and validated a risk-score model based on 13 prognostic FAM genes. Differential gene expression identified fatty acid synthase (FASN) as central to fatty acid metabolism in BC. FASN was differentially expressed between normal and tumor tissue, and was related to survival. In the CH dataset, FASN independently predicted muscle-invasive BC. FASN differential expression was significantly related to immune-cell infiltration and patients with low FASN expression responded better to immune checkpoint inhibitor (ICI) treatment. SREBF1 was predicted as the most significant transcription factor for FASN. Competing endogenous RNA network analysis suggested that lncRNA AC107027.3 may upregulate FASN by competitively binding miR-27A-3p, thereby regulating the immunotherapy response in BC. Dasatinib and temsirolimus are potential FASN-targeting drugs. Our model efficiently predicted prognosis in BC. FASN is central to fatty acid metabolism, and a potential indicator and regulator of ICI treatment.

show abstract

Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase

Cited by 17 publications

References 34 publications

ZBTB7A governs 2-DG-inhibited glycolysis by regulating GLUT1 in nasopharyngeal carcinoma

ZBTB7A governs 2-DG-inhibited glycolysis by regulating GLUT1 in nasopharyngeal carcinoma

Targeting SREBP-1-Mediated Lipogenesis as Potential Strategies for Cancer

Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer

Contact Info

Product

Resources

About